HUP0300548A3 - Polyol-ifn-betha conjugates - Google Patents

Polyol-ifn-betha conjugates

Info

Publication number
HUP0300548A3
HUP0300548A3 HU0300548A HUP0300548A HUP0300548A3 HU P0300548 A3 HUP0300548 A3 HU P0300548A3 HU 0300548 A HU0300548 A HU 0300548A HU P0300548 A HUP0300548 A HU P0300548A HU P0300548 A3 HUP0300548 A3 HU P0300548A3
Authority
HU
Hungary
Prior art keywords
betha
ifn
conjugates
polyol
betha conjugates
Prior art date
Application number
HU0300548A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of HUP0300548A2 publication Critical patent/HUP0300548A2/hu
Publication of HUP0300548A3 publication Critical patent/HUP0300548A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0300548A 1998-04-28 1999-04-28 Polyol-ifn-betha conjugates HUP0300548A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
PCT/US1999/009161 WO1999055377A2 (en) 1998-04-28 1999-04-28 Polyol-ifn-beta conjugates

Publications (2)

Publication Number Publication Date
HUP0300548A2 HUP0300548A2 (hu) 2003-06-28
HUP0300548A3 true HUP0300548A3 (en) 2005-07-28

Family

ID=22177687

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300548A HUP0300548A3 (en) 1998-04-28 1999-04-28 Polyol-ifn-betha conjugates

Country Status (30)

Country Link
US (3) US6638500B1 (cs)
EP (2) EP1421956B1 (cs)
JP (2) JP4574007B2 (cs)
KR (1) KR100622796B1 (cs)
CN (2) CN1187094C (cs)
AR (1) AR020070A1 (cs)
AT (2) ATE275422T1 (cs)
AU (1) AU762621B2 (cs)
BG (2) BG64694B1 (cs)
BR (1) BR9910023A (cs)
CA (2) CA2330451A1 (cs)
CY (1) CY1108022T1 (cs)
CZ (2) CZ298579B6 (cs)
DE (2) DE69920002T2 (cs)
DK (2) DK1075281T3 (cs)
EA (2) EA005495B1 (cs)
EE (1) EE05214B1 (cs)
ES (2) ES2285286T3 (cs)
HU (1) HUP0300548A3 (cs)
IL (1) IL139286A (cs)
NO (2) NO329749B1 (cs)
NZ (1) NZ507456A (cs)
PL (2) PL196533B1 (cs)
PT (2) PT1421956E (cs)
SI (2) SI1075281T1 (cs)
SK (2) SK286654B6 (cs)
TR (2) TR200003161T2 (cs)
TW (2) TWI232882B (cs)
UA (2) UA79430C2 (cs)
WO (1) WO1999055377A2 (cs)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
EP1656952B1 (en) * 1998-10-16 2013-12-18 Biogen Idec MA Inc. Polyalkylene glycol conjugates of interferon beta-1A and uses thereof
NZ510559A (en) 1998-10-16 2003-12-19 Biogen Inc Glycosylated interferon-beta fusion proteins that are as active as forms that are not fusion proteins
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
KR100642955B1 (ko) * 1999-04-23 2006-11-10 알자 코포레이션 방출성 결합 및 그를 함유하는 조성물
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
TR200101086A3 (cs) * 1999-10-15 2001-08-21
EP1270642B1 (en) * 1999-12-24 2011-08-31 Kyowa Hakko Kirin Co., Ltd. Branched polyalkylene glycols
DK1250154T3 (da) 2000-01-10 2009-08-17 Maxygen Holdings Ltd G-CSF-konjugater
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
ATE471956T1 (de) 2001-01-30 2010-07-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
IL159524A0 (en) 2001-07-11 2004-06-01 Maxygen Holdings Ltd G-csf conjugates
CN101700401B (zh) 2002-01-18 2013-08-14 比奥根艾迪克Ma公司 具有用于共轭生物活性化合物的部分的聚亚烷基二醇
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004060299A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
CA2511815A1 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
ATE431403T1 (de) 2003-03-20 2009-05-15 Bayer Healthcare Llc Fvii oder fviia varianten
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
AU2005209926B2 (en) * 2004-02-02 2007-09-06 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
AU2005244448B2 (en) 2004-05-17 2011-03-17 Ares Trading S.A. Hydrogel interferon formulations
WO2005117949A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Stabilized interferon liquid formulations
EA012281B1 (ru) 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
JP5243041B2 (ja) 2004-12-21 2013-07-24 ネクター セラピューティックス 安定化ポリマーチオール試薬
NZ584597A (en) 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
MX2007007587A (es) 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
CN101257926A (zh) * 2005-08-04 2008-09-03 尼克塔治疗亚拉巴马公司 G-csf部分与聚合物的轭合物
US20080219952A1 (en) 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
EA013816B1 (ru) 2005-09-01 2010-08-30 Арес Трейдинг С.А. Лечение неврита зрительного нерва
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
AU2007248680C1 (en) * 2006-05-02 2014-01-23 Allozyne, Inc. Non-natural amino acid substituted polypeptides
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
PL2026832T3 (pl) 2006-05-24 2012-08-31 Merck Serono Sa Skojarzony reżim interferonu beta i kladrybiny do leczenia stwardnienia rozsianego
CN101675071B (zh) * 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
WO2009080699A2 (en) 2007-12-20 2009-07-02 Merck Serono S.A. Peg-interferon-beta formulations
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
CN105524164A (zh) 2010-02-16 2016-04-27 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
US20130183280A1 (en) 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
JP6042335B2 (ja) 2010-09-15 2016-12-14 ノヴォ ノルディスク アー／エス 細胞取込みが低下した第ｖｉｉｉ因子変異体
KR101451357B1 (ko) * 2011-02-18 2014-10-15 주식회사 스템디알 Ｓｉｒｔ１ 발현 유도 물질을 포함하는 패혈증 또는 패혈증 쇼크의 예방 또는 치료용 조성물
BR112014000055A2 (pt) 2011-07-01 2017-06-13 Bayer Ip Gmbh polipeptídeos de fusão de relaxina e usos dos mesmos
CN109134642A (zh) * 2011-10-01 2019-01-04 株式会社糖锁工学研究所 加成糖链的多肽及含有该多肽的医药组合物
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
KR20140130705A (ko) 2012-02-29 2014-11-11 도레이 카부시키가이샤 체강액 저류 억제제
AU2014245917B2 (en) 2013-03-29 2017-09-28 Glytech, Inc. Polypeptide having sialylated sugar chains attached thereto
US11759500B2 (en) 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
SMT202100016T1 (it) 2014-08-19 2021-03-15 Biogen Ma Inc Metodo di pegilazione
ES2903448T3 (es) 2015-05-01 2022-04-01 Allysta Pharmaceuticals Inc Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
SI3310816T1 (sl) * 2015-06-19 2020-12-31 Eisai R&D Management Co.,Ltd. CYS80-konjugirani imunoglobulini
SG10201912972SA (en) 2015-11-09 2020-03-30 Univ Colorado Regents Compositions and methods for treatment of homocystinuria
CA3059592A1 (en) * 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
CN119097635A (zh) 2017-11-24 2024-12-10 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
BR112021012472A2 (pt) 2019-01-28 2021-11-30 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
CA3125320A1 (en) 2019-01-28 2020-08-06 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
JP2996415B2 (ja) 1994-03-31 1999-12-27 アムジエン・インコーポレーテツド 巨核球の成長と分化を刺激するモノｐｅｇ化ｍｇｄｆポリペプチド
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
ATE200030T1 (de) * 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
CA2296770A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
DE69936409T2 (de) 2008-04-17
CN1637020A (zh) 2005-07-13
HK1076115A1 (en) 2006-01-06
EP1421956B1 (en) 2007-06-27
SK286217B6 (sk) 2008-05-06
CZ298579B6 (cs) 2007-11-14
UA79430C2 (en) 2007-06-25
PL193352B1 (pl) 2007-02-28
US7357925B2 (en) 2008-04-15
NO20100324L (no) 2000-12-28
NO20005337L (no) 2000-12-28
PT1075281E (pt) 2004-11-30
ATE275422T1 (de) 2004-09-15
SK286654B6 (sk) 2009-03-05
CN100335503C (zh) 2007-09-05
ES2224649T3 (es) 2005-03-01
AR020070A1 (es) 2002-04-10
PL344490A1 (en) 2001-11-05
AU3767499A (en) 1999-11-16
TWI232882B (en) 2005-05-21
DK1421956T3 (da) 2007-10-01
TWI266800B (en) 2006-11-21
CA2565375A1 (en) 1999-11-04
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
NZ507456A (en) 2003-10-31
WO1999055377A2 (en) 1999-11-04
EA200001111A1 (ru) 2001-04-23
CA2330451A1 (en) 1999-11-04
SI1421956T1 (sl) 2007-10-31
PT1421956E (pt) 2007-07-13
EP1421956A1 (en) 2004-05-26
BG104871A (en) 2001-07-31
DE69920002D1 (de) 2004-10-14
ES2285286T3 (es) 2007-11-16
SI1075281T1 (en) 2005-02-28
BR9910023A (pt) 2000-12-26
KR20010071158A (ko) 2001-07-28
IL139286A0 (en) 2001-11-25
CZ20003995A3 (en) 2001-06-13
AU762621B2 (en) 2003-07-03
JP2010184929A (ja) 2010-08-26
KR100622796B1 (ko) 2006-09-13
ATE365563T1 (de) 2007-07-15
JP2002512983A (ja) 2002-05-08
WO1999055377A3 (en) 1999-12-29
US7700314B2 (en) 2010-04-20
HUP0300548A2 (hu) 2003-06-28
UA66857C2 (uk) 2004-06-15
EP1075281A2 (en) 2001-02-14
IL139286A (en) 2005-12-18
WO1999055377A9 (en) 2000-03-02
JP4574007B2 (ja) 2010-11-04
SK16222000A3 (sk) 2001-04-09
CY1108022T1 (el) 2013-09-04
TR200003161T2 (tr) 2001-01-22
BG109291A (en) 2006-04-28
NO329749B1 (no) 2010-12-13
EA200300382A1 (ru) 2005-02-24
BG65046B1 (bg) 2007-01-31
PL196533B1 (pl) 2008-01-31
US20040043002A1 (en) 2004-03-04
NO332224B1 (no) 2012-07-30
US6638500B1 (en) 2003-10-28
US20070141620A1 (en) 2007-06-21
TR200101751T2 (tr) 2002-05-21
NO20005337D0 (no) 2000-10-23
CN1302209A (zh) 2001-07-04
BG64694B1 (bg) 2005-12-30
EA005495B1 (ru) 2005-02-24
HK1038194A1 (en) 2002-03-08
CZ298597B6 (cs) 2007-11-21
DK1075281T3 (da) 2005-01-03
EE200000614A (et) 2002-04-15
CN1187094C (zh) 2005-02-02
DE69920002T2 (de) 2005-09-22
DE69936409D1 (de) 2007-08-09
EA003789B1 (ru) 2003-10-30

Similar Documents

Publication Publication Date Title
HUP0300548A3 (en) Polyol-ifn-betha conjugates
DE69924108D1 (en) Offshore-bohrsystem
GB2339200B (en) Genostics
DE69918845D1 (en) Polyketonlösung
GB9713980D0 (en) New conjugates
GB2337049B (en) Trisresorcinyltriazines
PL347427A1 (en) Thiazole-derivatives
GB2336996B (en) Multi-desk
GB9809421D0 (en) Aroma-vac
DE59905941D1 (en) Methoximinophenylessigsäureamide
GB9815709D0 (en) Ospro-ski
GB9803582D0 (en) Post-protectors
GB9827813D0 (en) Pharmaceutical conjugates
GB9817832D0 (en) Curvers
GB9818451D0 (en) Conjugates
GB2337526B (en) Easy rockeries
GB9825105D0 (en) Pharamaceutical conjugates
GB9912039D0 (en) Gene-activating conjugates
HK1033279A (en) Hemoglobin-polysaccharide conjugates
GB9801608D0 (en) Camrar II
PL108545U1 (en) Cprner piece
AU135781S (en) Rook - chess piece
GB9803578D0 (en) Vac-Mag
GB9815448D0 (en) Tranelock
GB9805071D0 (en) Vangs

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished